THAR has 36-month beta value of 1.35. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for THAR is 1.13M, and currently, short sellers hold a 43.97% ratio of that float. The average trading volume of THAR on November 13, 2024 was 1.01M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
THAR) stock’s latest price update
Tharimmune Inc (NASDAQ: THAR)’s stock price has plunge by -2.56relation to previous closing price of 2.15. Nevertheless, the company has seen a -25.18% plunge in its stock price over the last five trading sessions. accesswire.com reported 2024-11-13 that BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With particular utility in cancer therapies, this innovative platform is designed to enhance the delivery of therapeutic antibodies and peptides, which are often limited by enzymatic degradation and poor systemic circulation.
THAR’s Market Performance
Tharimmune Inc (THAR) has experienced a -25.18% fall in stock performance for the past week, with a 8.66% rise in the past month, and a -30.17% drop in the past quarter. The volatility ratio for the week is 9.86%, and the volatility levels for the past 30 days are at 17.33% for THAR. The simple moving average for the last 20 days is -11.91% for THAR stock, with a simple moving average of -49.86% for the last 200 days.
THAR Trading at -15.32% from the 50-Day Moving Average
After a stumble in the market that brought THAR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.43% of loss for the given period.
Volatility was left at 17.33%, however, over the last 30 days, the volatility rate increased by 9.86%, as shares sank -18.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.09% lower at present.
During the last 5 trading sessions, THAR fell by -26.90%, which changed the moving average for the period of 200-days by -70.91% in comparison to the 20-day moving average, which settled at $2.38. In addition, Tharimmune Inc saw -72.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at THAR starting from MILBY RANDY, who purchase 2,500 shares at the price of $2.09 back on Oct 08 ’24. After this action, MILBY RANDY now owns 12,934 shares of Tharimmune Inc, valued at $5,221 using the latest closing price.
Appajosyula Sireesh, the Chief Operating Officer of Tharimmune Inc, purchase 5,000 shares at $1.93 during a trade that took place back on Oct 08 ’24, which means that Appajosyula Sireesh is holding 16,364 shares at $9,650 based on the most recent closing price.
Stock Fundamentals for THAR
The total capital return value is set at -3.68. Equity return is now at value -454.53, with -257.79 for asset returns.
Currently, EBITDA for the company is -9.3 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.30.
Conclusion
To put it simply, Tharimmune Inc (THAR) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
